Bi/ond

If you are in the market for a new microfluidic pump, we have good news for you! Considering some key topics that scientists were looking for in a pump and based on our own experience in the lab, 𝘄𝗲 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗮𝗻𝗱 𝗽𝗿𝗼𝗱𝘂𝗰𝗲𝗱 𝗼𝘂𝗿 𝘃𝗲𝗿𝘆 𝗼𝘄𝗻 𝗺𝗶𝗰𝗿𝗼𝗳𝗹𝘂𝗶𝗱𝗶𝗰 𝗽𝘂𝗺𝗽. And today, we are introducing it to you : 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹𝗗𝗥𝗜𝗩𝗘™ Find out more about this new product and what it can mean for your research capabilities. #gobiond #newproduct #microfluidic #pump #celldrive #organonchip

𝗢𝘂𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝘀𝗼 𝗳𝗮𝗿... From groundbreaking innovations to team adventures, take a peek into how Bi/ond has evolved over the years. This video captures the heart of what we do —both in the lab and beyond! 🎬 Watch now and see how we’re advancing technology while building a vibrant, collaborative workplace. #gobiond #tbt #InnovationInAction #TeamCulture #GrowingTogether #LifeAtBiond

𝗖𝗼-𝗰𝘂𝗹𝘁𝘂𝗿𝗲 𝗼𝗳 𝗰𝗮𝗿𝗱𝗶𝗼𝗺𝘆𝗼𝗰𝘆𝘁𝗲𝘀 𝗮𝗻𝗱 𝗲𝗻𝗱𝗼𝘁𝗵𝗲𝗹𝗶𝗮𝗹 𝗰𝗲𝗹𝗹𝘀 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗺𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲 This group of researchers (see below) have developed a 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗵𝘂𝗺𝗮𝗻 𝗰𝗲𝗹𝗹-𝗯𝗮𝘀𝗲𝗱 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝘁𝗶𝘀𝘀𝘂𝗲 𝗺𝗼𝗱𝗲𝗹 𝘁𝗵𝗮𝘁 𝗯𝗿𝗶𝗱𝗴𝗲𝘀 𝘁𝗵𝗲 𝗴𝗮𝗽 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗶𝗻 𝘃𝗶𝘁𝗿𝗼 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗮𝗻𝗱 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗵𝘂𝗺𝗮𝗻 𝘀𝗲𝘁𝘁𝗶𝗻𝗴𝘀. 🫀 ***KEY FINDINGS*** 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗠𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻: The cardiac tissue model shows improved maturity and physiological relevance, making it more representative of human cardiac tissue. 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹𝗶𝘁𝘆 𝗖𝗼𝗻𝗳𝗶𝗿𝗺𝗮𝘁𝗶𝗼𝗻: The model’s functionality was confirmed by assessing the effects of 32 compounds using multielectrode arrays. It predicted cardiac effects with impressive accuracy (91%), sensitivity (90%), and specificity (100%). 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗛𝘂𝗺𝗮𝗻 𝗦𝗲𝘁𝘁𝗶𝗻𝗴𝘀: The standardized model allows accurate translation of in vitro data to human contexts, making it highly valuable for biomedical research and cardiotoxicity testing. 📚 Read the full article here: 𝙁𝙪𝙣𝙘𝙩𝙞𝙤𝙣𝙖𝙡 𝙝𝙪𝙢𝙖𝙣 𝙘𝙚𝙡𝙡-𝙗𝙖𝙨𝙚𝙙 𝙫𝙖𝙨𝙘𝙪𝙡𝙖𝙧𝙞𝙨𝙚𝙙 𝙘𝙖𝙧𝙙𝙞𝙖𝙘 𝙩𝙞𝙨𝙨𝙪𝙚 𝙢𝙤𝙙𝙚𝙡 𝙛𝙤𝙧 𝙗𝙞𝙤𝙢𝙚𝙙𝙞𝙘𝙖𝙡 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙖𝙣𝙙 𝙩𝙚𝙨𝙩𝙞𝙣𝙜 https://lnkd.in/euYHpSGK 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿! Authors : Maria Koivisto, Tuomas Tolvanen, Tarja Toimela, Ilkka Miinalainen, Antti Kiviaho, Juha Kesseli, @Matti Nykter, @Lauri Eklund & Tuula Heinonen #BiomedicalResearch #CardiacHealth #StemCells #ScienceAdvances

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗙𝘂𝗹𝗹 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 : 𝗔 𝗠𝗶𝗰𝗿𝗼𝗳𝗹𝘂𝗶𝗱𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿-𝗼𝗻-𝗖𝗵𝗶𝗽 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝘀 𝗗𝗿𝘂𝗴 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗨𝘀𝗶𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗼𝘁𝘆𝗽𝗶𝗰 𝗧𝘂𝗺𝗼𝗿 𝗦𝗹𝗶𝗰𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 to discover how you can also advance your cancer research with Bi/ond's #OrganOnChip technology.

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗢𝗿𝗴𝗮𝗻-𝗼𝗻-𝗖𝗵𝗶𝗽 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 Determining the most effective therapy for individual cancer patients remains a complex challenge. Addressing this diagnostic gap requires innovative approaches, such as direct assessment of therapy response in viable tumour specimens. In a groundbreaking study led by Sanjiban Chakrabarty at Erasmus MC, researchers established a cutting-edge cancer-on-chip (CoC) platform. Leveraging Bi/ond’s inCHIPit™ and comPLATE™ technologies, they cultured breast cancer PDX slices and prostate cancer PDX slices. Key findings from the study: 🟢 𝗘𝘅𝘁𝗲𝗻𝗱𝗲𝗱 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 𝗧𝗶𝗺𝗲 The CoC platform significantly prolonged the viable culture time of prostate cancer PDX slices (up to 7 days) and breast cancer PDX slices (up to 14 days). This extended duration is crucial for studying dynamic changes in therapy response, including the emergence of resistance. 🟢 𝗣𝗿𝗲𝘀𝗲𝗿𝘃𝗲𝗱 𝗠𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗚𝗲𝗻𝗲 𝗘𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 Throughout the culture period, the CoC platform maintains tissue morphology, gene expression patterns, and proliferative capacity in both breast and prostate cancer PDX slices. 🟢 𝗜𝗻 𝗩𝗶𝘃𝗼 𝗥𝗲𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 The CoC system faithfully replicates the in vivo response to cisplatin therapy (for breast cancer) and apalutamide treatment (for prostate cancer). 📊 𝗩𝗶𝘀𝘂𝗮𝗹𝗶𝘇𝗶𝗻𝗴 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 The accompanying figure illustrates the therapeutic response in breast tumour slices. After 3 days of cisplatin exposure, the CoC platform revealed increased TUNEL-positive (apoptotic) and decreased EdU-positive (replicating) staining in cisplatin-sensitive tumour slices, consistent with in vivo findings. Interestingly, breast PDX tissue cultured in the CoC platform showed a stronger response to cisplatin treatment than the ex-vivo culture method. The authors suggested that the CoC platform could provide a more optimal drug delivery approach compared to their standard culture method. 📰 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗙𝘂𝗹𝗹 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 : 𝗔 𝗠𝗶𝗰𝗿𝗼𝗳𝗹𝘂𝗶𝗱𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿-𝗼𝗻-𝗖𝗵𝗶𝗽 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝘀 𝗗𝗿𝘂𝗴 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗨𝘀𝗶𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗼𝘁𝘆𝗽𝗶𝗰 𝗧𝘂𝗺𝗼𝗿 𝗦𝗹𝗶𝗰𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗲: https://lnkd.in/ejnau8Ht Ready to enhance your cancer models? Learn more about inCHIPit™ and comPLATE™ https://lnkd.in/ge6jJBm #gobiond #organonachip #cancer #breastcancer #prostatecancer #personalizedmedicine

We have a new team member!! Tien H. Le joins our financial team to support in administration and financial reporting, as well as maintain our accounting integrity and up-to-date financial information. Read below a bit about why he decided to join and help us welcome Tien to the Bi/ond team! #newhire #gobiond #team #financialcontroller

As we celebrate World Animal Day today, we envision a future where animal testing is no longer necessary. Our organ-on-chip technology is a significant step towards this goal, offering a more humane alternative. We are proud to be at the forefront of this transformation, working towards a world where scientific innovation and animal welfare go hand in hand. Together, we can create a brighter future for both animals and humans. #gobiond #WorldAnimalDay #AnimalWelfare #ScientificInnovation #ooc 

𝗪𝗵𝗮𝘁 𝗺𝗮𝗸𝗲𝘀 𝘁𝗵𝗲 𝗠𝗨𝗦𝗯𝗶𝘁™ 𝘁𝗿𝘂𝗹𝘆 𝘂𝗻𝗶𝗾𝘂𝗲? ☑ More Physiologically Relevant Muscle Tissue Formation ☑ Versatile Imaging ☑ Convenient Retrieval ☑ Tissue Pacing and Training ☑ Microfluidic Integration ☑ Compatible with various Cells, Reagents and Hydrogels ☑ Cost-Effectiveness By utilizing the MUSbit™, you can 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗺𝘂𝘀𝗰𝗹𝗲 𝗺𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗲𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗰𝗲𝗹𝗹 𝘀𝘁𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻, 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁𝗹𝘆 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. Ready to learn more about the MUSbit™ and its groundbreaking capabilities? 📩 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗼𝘂𝗿 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲 to explore the endless possibilities! https://lnkd.in/eg_C4KnA #gobiond #musbit #ooc #download #brochure #microfluidic

Use Heart for action 💙 It is time that cardiovascular disease is taken seriously. This affection is responsible for 𝗼𝘃𝗲𝗿 𝟮𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗱𝗲𝗮𝘁𝗵𝘀 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 𝗼𝗻 𝗮 𝘆𝗲𝗮𝗿𝗹𝘆 𝗯𝗮𝘀𝗶𝘀. However, many countries do not prioritize hearth health and national policies for cardiovascular disease are lacking or insufficient. The goal of this World Heart Day does not stop today, but will span over the next two years to not only raise awareness but also empower individual and global action to improve the situation of current and future individuals with cardiovascular problems. At Bi/ond, we have a big research focus to 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗺𝘂𝘀𝗰𝗹𝗲 𝗺𝗼𝗱𝗲𝗹𝘀 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗰𝗮𝗻 𝗲𝘅𝗽𝗹𝗮𝗶𝗻 𝗺𝘂𝘀𝗰𝗹𝗲 𝗮𝗳𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗵𝗼𝘄 𝗱𝗿𝘂𝗴𝘀 𝗰𝗮𝗻 𝗶𝗻𝗳𝗹𝘂𝗲𝗻𝗰𝗲 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻. If you are interested in learning more, do not hesitate to contact our team. https://lnkd.in/g3pKFHm #gobiond #cardiovascular #WHD #worldheartday #cardiacresearch #ooc

Thank you very much, Ljubljana! With so many insightful speakers and terrific poster discussions, the European Muscle Conference (EMC) 2024 has been a hit and Bi/ond are honoured to have been able to attend and proudly support the event. The sessions spanned the entire #muscle #research spectrum, from talks on exercise physiology all the way to new methodologies to study muscle mechanics 𝙞𝙣 𝙫𝙞𝙩𝙧𝙤. It was a delight to hear from many of the prominent researchers in the field. We look forward to continuing to support and collaborate with many of these research pioneers and help push those boundaries a little bit more. #2024 #EMC #OoC #Muscleresearch